Overview
ABCL market data
Price History
ABCL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.49 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.16 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.75 – $8.42 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $2.4K · P/B 1.06 · P/S 30.34.
Company news
Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price TargetBenzinga · Jul 7, 2026, 11:55 AM
8-K filing — AbCellera Biologics Inc. (ABCL)SEC EDGAR · Jul 6, 2026, 6:53 PM
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera CollaborationBenzinga · Jun 17, 2026, 5:00 PM
Jazz Pharma And AbCellera Announce Preclinical Research Collaboration, Option And License Agreement To Discover, Develop Next-Gen T-Cell Engaging Multispecific AntibodiesBenzinga · Jun 17, 2026, 11:15 AM
Earnings Scheduled For May 11, 2026Benzinga · May 11, 2026, 11:11 AM